Updates for 2021
FDLI remains committed to providing high-quality educational programs while keeping our members and event attendees safe during the current pandemic. With this in mind, we are excited to announce that the 2021 Introduction to Biologics & Biosimilars Law and Regulation Course will be a completely virtual event. Please know we are actively exploring options to ensure an engaging and enjoyable experience. Be sure to check the course website regularly for additional announcements and updates.
Explore the regulation of biological products, including biotechnology–derived therapeutic proteins, human tissue, gene, and cell products. Learn about the abbreviated pathway to market for biosimilar biological products and associated intellectual property issues, including exclusivity and biologics patent litigation. Case studies, hypotheticals, and ample time for Q&A is provided.
Agenda Highlights
- Regulatory processes for biologics
- Review and approval process
- Regulation of biological/drug development
- Biologics License Application (BLA)
- Biosimilar biologic products
- Post-approval safety issues
- Regulation of biological manufacturing
- Advertising and promotion requirements
- Enforcement tools and procedures
- Changes to the statutory framework for regenerative medicine
Statutes Covered
- The 1902 Biologics Act
- Federal Food, Drug & Cosmetic Act (FD&C Act)
- Public Health Service Act of 1944 (PHSA)
- Food and Drug Administration Amendments Act of 2007 (FDAAA)
- Biologics Price Competition and Innovation Act (BPCIA)
- Food and Drug Administration Safety and Innovation Act (FDASIA)
- Prescription Drug User Fee Act and Biosimilars User Fee Act
- 21st Century Cures Act
Attendee Resources
These valuable takeaways will be provided onsite:
- A binder of speaker handouts and related reference materials.
- Access to an electronic copy of the FDCA Statutory Supplement, 2018
Who Should Attend
- New legal and regulatory professionals
- Seasoned practitioners new to the topic or wanting a refresher
Register by September 24 and SAVE!
Industry & Firms
- +$400 for non-members
- +$100 after 9/24/21
Non-Profit
- +$200 for non-members
- +$100 after 9/24/21
Government
- +$200 for non-members
- +$100 after 9/24/21
Academic
- +$200 for non-members
- +$100 after 9/24/21
Student
- full-time students only
- transcripts required
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Add This Must-Have Reference to Your Registration
Purchase A Practical Guide to FDA’s Food and Drug Law and Regulation, 7th Edition to have an overview of the key legal and regulatory topics at your fingertips. Order your copy today and it will be shipped directly to your office.
You can transfer your registration to another person at your organization for no cost by notifying us of the change. If you notify FDLI in writing at least five business days prior to the meeting, you can cancel your registration for a full refund (less a $75 fee). Refunds will be applied against the original form of payment.
Our event policies are listed here. If you should have any further questions, please contact us at [email protected] or 800-956-6293.
Agenda
subject to change
Curriculum Advisor:
Scott M. Lassman, Principal, Lassman Law & Policy
Tuesday, October 5
12:00 PM
FDLI Welcome and Announcements
Khara L. Minter, Assistant Director, Training Programs, FDLI
12:05–1:15 PM
Overview of Biological Products Law and the Regulation and FDA’s Regulatory Processes
1:15–1:25 PM
Break
1:25–2:40 PM
Introduction to FDA Review and Approval of Biological Products
2:40–2:50 PM
Break
2:50–3:50 PM
Regulation of Biological/Drug Development
3:50–4:00 PM
Break
4:00–5:00 PM
Regenerative Medicine and Advanced Therapies (RMATs)
Wednesday, October 6
12:00 PM
FDLI Welcome and Announcements
Khara L. Minter, Assistant Director, Training Programs, FDLI
12:05–1:15 PM
Biologics License Applications (BLA)
1:15–1:25 PM
Break
1:25–2:40 PM
Biosimilar Biological Products
2:40–2:55 PM
Break
2:55–4:05 PM
Post-Approval Pharmacovigilance
4:05–5:00 PM
New, Emerging, and Continually Interesting Issues
Thursday, October 7
12:00 PM
FDLI Welcome and Announcements
Khara L. Minter, Assistant Director, Training Programs, FDLI
12:05–1:20 PM
Regulation of Biological Manufacturing
1:20–1:30 PM
Break
1:30–2:45 PM
Regulation of Biological Marketing
2:45–3:00 PM
Break
3:00–4:30 PM
Violations, Enforcement, and International Issues
4:30 PM
Adjournment
Continuing Legal Education
FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.